If you have gone looking for help with numbness and tingling after chemotherapy, you have probably been pointed toward acetyl-L-carnitine. It is sold widely as nerve support. It is in the neuropathy formulas on the shelf at every supplement store, and plenty of practitioners recommend it.
The American Society of Clinical Oncology’s guideline says clinicians should not offer it, and should discourage its use.
Not “there is limited evidence.” Not “more research is needed.” Discourage.
What the guideline says
ASCO’s guideline on chemotherapy-induced peripheral neuropathy states that clinicians “should not offer, and should discourage use of, acetyl-L-carnitine for the prevention of CIPN.”
The rating attached: evidence-based, harms outweigh benefits, high quality of evidence, strong recommendation. In guideline language that combination is about as emphatic as it gets. Most recommendations in this area are graded low-quality and conditional. This one is not.
The Society for Integrative Oncology’s breast cancer guideline — a guideline written by the integrative oncology field — reaches the same conclusion and assigns acetyl-L-carnitine Grade H, its designation for harm: “there is moderate or high certainty that the harms outweigh the benefits — discourage the use of this modality.”
The concern comes from trial data suggesting acetyl-L-carnitine may worsen neuropathy rather than prevent it.
One precision worth making, since precision is the point of this article. Both of those recommendations are written about prevention — taking it to stop neuropathy from developing. Neither guideline evaluated it as a treatment for neuropathy you already have.
That is not a loophole. A supplement with high-quality evidence of worsening nerve symptoms when given prophylactically is not an obvious candidate for the same nerves once they are already damaged, and no guideline recommends it for that either. But if someone tells you the guidelines say it is harmful in established CIPN, they are stating more than the guidelines state — and this article would be a poor place to make that mistake.
Why you have probably never heard this
Because it is an unwelcome finding for everyone who might tell you.
Supplement retailers have no reason to mention it. Practitioners who have recommended it for years have to revise a habit. And it is a genuinely counterintuitive result — carnitine is involved in nerve metabolism, the mechanism sounds reasonable, and reasonable-sounding mechanisms are how most supplements get sold.
It is the most under-reported line in the integrative oncology literature, and it is a good example of why mechanism is not evidence.
What else the guideline says — the uncomfortable part
If you are hoping the guideline names a replacement, it mostly does not.
For established chemotherapy-induced neuropathy, ASCO says that outside a clinical trial, no recommendation can be made for exercise therapy, acupuncture, scrambler therapy, gabapentin, pregabalin, topical gels, tricyclic antidepressants or oral cannabinoids. Not that they do not work — that the evidence is not sufficient to recommend either way.
The one thing it says clinicians may offer for painful CIPN is duloxetine, a prescription medication, on intermediate-quality evidence with benefits roughly balanced against harms. That is a conversation for your oncologist.
For prevention, the guideline also says not to offer vitamin E, vitamin B, gabapentin or pregabalin, among roughly two dozen others.
So what is worth doing?
The evidence gap is real, and pretending otherwise does not help you. But “no guideline-recommended treatment” is not the same as “nothing to do.”
Tell your oncologist, early and specifically. Some neuropathy is dose-dependent, and dose modification is a real clinical decision that gets made better with accurate information. Vague reporting — “my feet feel weird sometimes” — leads to vague decisions. Describe which fingers and toes, whether it is numbness or burning, whether it is affecting buttons, keys, or walking.
Take the safety issues seriously. Reduced sensation in the feet changes your falls risk, and falls are one of the ways a manageable problem becomes a serious one. Loose rugs, night lighting, shoes with real support, grab bars if balance is affected. Unglamorous and genuinely protective.
Protect your feet. Reduced sensation means you may not feel a blister, a burn, or a stone in your shoe. Daily visual checks, the same way people with diabetic neuropathy are taught.
Ask your care team about function, not just sensation. Grip, balance and gait are what determine whether neuropathy limits your daily life or is mostly an annoyance, and they are worth assessing and tracking separately from how your feet feel. ASCO makes no recommendation for or against exercise therapy in established CIPN — the evidence is not there either way — so treat any program you are offered as unproven for the nerve symptoms themselves, whatever else it may do for you.
Ask about duloxetine if pain is the dominant symptom. It is the only thing in the guideline with a positive recommendation — may be offered, on intermediate-quality evidence, with a moderate strength of recommendation and benefits judged roughly equal to harms.
And bring us the bottles. If acetyl-L-carnitine is in your cabinet, that is a conversation worth having — with us or with your oncology team.
One more thing
Chemotherapy-induced neuropathy is not diabetic neuropathy. Different cause, different distribution, different natural history, different evidence base. Nearly every neuropathy clinic in Oklahoma is built around the diabetic version, and protocols developed for it are often applied to CIPN without much thought about whether that transfer is justified.
If a clinic offers you a neuropathy program, ask directly whether their protocol was studied in chemotherapy-induced neuropathy specifically. It is a fair question and the answer tells you a lot.
This article is educational and is not medical advice. Do not start or stop any supplement or medication without talking to your oncology team. Venturis Clinic is not a cancer treatment center and does not treat cancer.
Written by Dr. Alvin Philipose, B.S., B.S., DC, ICCP
Reviewed 20 August 2026
